Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National ...

Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National Cancer Institute
17. Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in
patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (15): 3262-9, 2002.
[PUBMED Abstract]
18. Ansell SM, Ristow KM, Habermann TM, et al.: Subsequent chemotherapy regimens are well tolerated after
radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20
(18): 3885-90, 2002. [PUBMED Abstract]
19. Davies AJ, Rohatiner AZ, Howell S, et al.: Tositumomab and iodine I 131 tositumomab for recurrent
indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22 (8): 1469-79, 2004. [PUBMED
Abstract]
20. Fisher RI, Kaminski MS, Wahl RL, et al.: Tositumomab and iodine-131 tositumomab produces durable
complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-
Hodgkin's lymphomas. J Clin Oncol 23 (30): 7565-73, 2005. [PUBMED Abstract]
21. Leahy MF, Seymour JF, Hicks RJ, et al.: Multicenter phase II clinical study of iodine-131-rituximab
radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 24 (27):
4418-25, 2006. [PUBMED Abstract]
22. Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant
prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine,
cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and
mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma
Study Group (GLSG). Blood 108 (13): 4003-8, 2006. [PUBMED Abstract]
23. van Oers MH, Klasa R, Marcus RE, et al.: Rituximab maintenance improves clinical outcome of
relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during
induction: results of a prospective randomized phase 3 intergroup trial. Blood 108 (10): 3295-301, 2006.
[PUBMED Abstract]
24. Brice P, Simon D, Bouabdallah R, et al.: High-dose therapy with autologous stem-cell transplantation
(ASCT) after first progression prolonged survival of follicular lymphoma patients included in the
prospective GELF 86 protocol. Ann Oncol 11 (12): 1585-90, 2000. [PUBMED Abstract]
25. Freedman A, Friedberg JW, Gribben J: High-dose therapy for follicular lymphoma. Oncology (Huntingt) 14
(3): 321-6, 329; discussion 330-2, 338, 2000. [PUBMED Abstract]
26. Khouri IF, McLaughlin P, Saliba RM, et al.: Eight-year experience with allogeneic stem cell
transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,
cyclophosphamide, and rituximab. Blood 111 (12): 5530-6, 2008. [PUBMED Abstract]
27. Sebban C, Brice P, Delarue R, et al.: Impact of rituximab and/or high-dose therapy with autotransplant at
time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26 (21): 3614-20, 2008.
[PUBMED Abstract]
28. Thomson KJ, Morris EC, Milligan D, et al.: T-cell-depleted reduced-intensity transplantation followed by
donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term
survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 28 (23): 3695-700, 2010.
[PUBMED Abstract]
29. Lenz G, Dreyling M, Schiegnitz E, et al.: Myeloablative radiochemotherapy followed by autologous stem
cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a
prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (9): 2667-74,
2004. [PUBMED Abstract]
30. Tsimberidou AM, O'Brien S, Khouri I, et al.: Clinical outcomes and prognostic factors in patients with
Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell
transplantation. J Clin Oncol 24 (15): 2343-51, 2006. [PUBMED Abstract]
31. Montoto S, Davies AJ, Matthews J, et al.: Risk and clinical implications of transformation of follicular
lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25 (17): 2426-33, 2007. [PUBMED Abstract]
32. Yuen AR, Kamel OW, Halpern J, et al.: Long-term survival after histologic transformation of low-grade
follicular lymphoma. J Clin Oncol 13 (7): 1726-33, 1995. [PUBMED Abstract]
33. Bastion Y, Sebban C, Berger F, et al.: Incidence, predictive factors, and outcome of lymphoma
transformation in follicular lymphoma patients. J Clin Oncol 15 (4): 1587-94, 1997. [PUBMED Abstract]
file:///Users/mauriciolema/Documents/MLMGuias_09_LinfomaNoHodgkin.webarchive
29/09/11 6:15
Página 49 de 61